Mereo Biopharma Group plc insider trading

Every open-market purchase and sale by Mereo Biopharma Group plc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Mereo Biopharma Group plc’s insiders pay?

From May 23, 2024 to September 16, 2024, 6 insiders reported 0 open-market purchases and 12 sales not made under a pre-set plan in Mereo Biopharma Group plc.

Mereo Biopharma Group plc: each insider's record
Insider	Role	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Hughes-Wilson Alexandra	See Remarks	—	—	3	—	September 16, 2024
Fox Christine Ann	Chief Financial Officer	—	—	2	—	September 16, 2024
Lewicki John A.	Chief Scientific Officer	—	—	2	—	September 16, 2024
Scots-Knight Denise	Chief Executive Officer	—	—	2	—	September 16, 2024
Sermon Charles	General Counsel	—	—	2	—	September 16, 2024
Pakianathan Deepika	Director	—	—	1	—	August 23, 2024

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Mereo Biopharma Group plc · Funds · Politicians